63 patents
Utility
Ion channel modulators
9 Jan 24
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy, Marion Wittmann
Filed: 30 May 19
Utility
Formulations of Ion Channel Modulators and Methods of Preparation and Use of Ion Channel Modulators
2 Nov 23
The present invention is directed to, in part, compositions or dosage forms comprising fused heteroaryl compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Gabriel MARTINEZ BOTELLA, Walter J. LUNSMANN, Sapna Makhija GARAD, David REED, Andrew Mark GRIFFIN, Michael Kristopher Mathieu KAHLIG, Brian Edward MARRON, Carlos LOYA
Filed: 25 Nov 20
Utility
Compounds and Their Methods of Use
12 Oct 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 10 Mar 23
Utility
KCNT1 inhibitors and methods of use
3 Oct 23
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1).
Gabriel Martinez Botella, Andrew Mark Griffin
Filed: 2 Nov 21
Utility
Compounds and their methods of use
3 Oct 23
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 28 May 20
Utility
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
26 Sep 23
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron, Carlos Loya
Filed: 25 Nov 20
Utility
Ion Channel Modulators
14 Sep 23
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy
Filed: 18 Oct 22
Utility
KCNT1 Inhibitors and Methods of Use
14 Sep 23
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1).
Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN
Filed: 23 Mar 21
Utility
Compounds and their methods of use
22 Aug 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 4 Apr 18
Utility
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator
22 Aug 23
The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-a]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 26 Mar 21
Utility
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator
22 Aug 23
The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-α]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Filed: 23 Mar 22
Utility
KCNT1 Inhibitors and Methods of Use
13 Jul 23
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1).
Andrew Mark GRIFFIN, Gabriel MARTINEZ BOTELLA
Filed: 6 Jul 21
Utility
Compounds and Their Methods of Use
13 Jul 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 4 Oct 22
Utility
Hemi-citrate salts of GABA-A positive allosteric modulator and crystalline form thereof
11 Jul 23
Disclosed herein are hemi-citrate salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof, and methods of their use.
Doris Neville, Ahmad Hashash, Karl Hansen, Johann Chan
Filed: 25 May 22
Utility
Formulations of T-type calcium channel modulators and methods of use thereof
16 May 23
Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).
Preetam Ghogale
Filed: 28 Jul 21
Utility
Fused Heteroaryl Compounds, and Methods Thereof for Treating Diseases, Disorders, and Conditions Relating to Aberrant Function of a Sodium Channel
4 May 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran REDDY, Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Brian Edward MARRON
Filed: 19 Jan 22
Utility
Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity
18 Apr 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 28 Nov 17
Utility
Ion Channel Modulators
2 Feb 23
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran REDDY, Gabriel MARTINEZ BOTELLA, Andrew Mark GRIFFIN, Brian Edward MARRON, Carlos LOYA
Filed: 25 Nov 20
Utility
Substituted pyridines as ion channel modulators
22 Nov 22
Andrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella, Kiran Reddy
Filed: 29 May 20
Utility
Compounds and their methods of use
8 Nov 22
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current.
Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
Filed: 13 Feb 18